Comparison of the 2 genetic groups, HOX11L2 positive versus HOX11L2 negative, in terms of EFS and survival: 3-year estimate rates and the hazard ratio estimates
. | HOX11L2-positive, N = 35 . | HOX11L2-negative,*N = 118 . |
|---|---|---|
| EFS | ||
| 3-year rate, % (SE %) | 75.5 (8.1) | 68.3 (5.0) |
| Hazard ratio (95% CI) | 0.84 (0.40-1.80) | 1 |
| Survival | ||
| 3-year rate, % (SE %) | 77.3 (8.4) | 75.3 (4.6) |
| Hazard ratio (95% CI) | 0.85 (0.37-1.95) | 1 |
. | HOX11L2-positive, N = 35 . | HOX11L2-negative,*N = 118 . |
|---|---|---|
| EFS | ||
| 3-year rate, % (SE %) | 75.5 (8.1) | 68.3 (5.0) |
| Hazard ratio (95% CI) | 0.84 (0.40-1.80) | 1 |
| Survival | ||
| 3-year rate, % (SE %) | 77.3 (8.4) | 75.3 (4.6) |
| Hazard ratio (95% CI) | 0.85 (0.37-1.95) | 1 |
This group included 118 patients: 10 patients with HOX11-high, 17 patients positive for SIL-TAL, 76 patients with other, and 15 additional patients who tested negative for HOX11L2 and not tested for HOX11 and SIL-TAL status.